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ABSTRACT
Osteoporosis isdefinedas reducedbonemineral densitywithahighriskoffragilefracture. Current availabletreatmentregimens include
antiresorptive drugs such as estrogen receptor analogues and bisphosphates and anabolic agents such as parathyroid hormone (PTH).
However, neither option is completely satisfactory because of adverse effects. It is thus highly desirable to identify novel anabolic agents
to improve future osteoporosis treatment. Osthole, a coumarin-like derivative extracted from Chinese herbs, has been shown to
stimulate osteoblast proliferation and differentiation, but its effect on bone formation in vivo and underlying mechanism remain
unknown. In this study, we found that local injection of Osthole significantly increased new bone formation on the surface of mouse
calvaria. Ovariectomy caused evident bone loss in rats, whereas Osthole largely prevented such loss, as shown by improved bone
microarchitecture, histomorphometric parameters, and biomechanical properties. In vitro studies demonstrated that Osthole activated
Wnt/b-catenin signaling, increased Bmp2 expression, and stimulated osteoblast differentiation. Targeted deletion of the b-catenin and
Bmp2 genes abolished the stimulatory effect of Osthole on osteoblast differentiation. Since deletion of the Bmp2 gene did not affect
Osthole-induced b-catenin expression and the deletion of the b-catenin gene inhibited Osthole-regulated Bmp2 expression in
osteoblasts, we propose that Osthole acts through b-catenin–BMP signaling to promote osteoblast differentiation. Our findings
demonstrate that Osthole could be a potential anabolic agent to stimulate bone formation and prevent estrogen deficiency–induced
bone loss.  2010 American Society for Bone and Mineral Research.
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Introduction
I
ncreased longevity and a changing lifestyle have significantly
increased the prevalence of osteoporosis, a skeletal disorder
characterized by reduced bone mineral density (BMD) and
deteriorating bone microarchitecture. Osteoporosis affects over
10 million Americans. Over 1.5 million osteoporotic fractures
occur every year and are a major cause of morbidity and
mortality with an annual cost of nearly $20 billion in the United
States.
(1–3)About40%ofwomenand13%ofmenage50yearsor
older will experience at least one fracture during their remaining
lifetime. The risk factors associated with osteoporotic fracture
include age, prior fracture, smoking, and systemic corticosteroid
use, and fracture incidence increases with age.
(4,5) Aging-
associated bone loss can be divided into two phases: a rapid
phasestartingatmenopauseandaslowphaseoccurringabout8
years after menopause and persisting until death. The rapid
phase is caused by estrogen insufficiency and mainly affects
trabecular bone. In contrast, the slow phase is a process believed
to be the result of a more complex, less well understood etiology
causing loss of both trabecular and cortical bone and affects
both men and women.
(6)
Current treatment regimens for osteoporosis fall into two
categories: antiresorptive drugs that inhibit osteoclast function
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1234such as estrogen and estrogen-receptor analogues and bispho-
sphates and anabolic drugs that induce osteoblastic bone
formation. While estrogen replacement has produced positive
results with respect to improved BMD and reduced fracture
incidence in early menopause, its prolonged use is restricted
becauseofpotentialcomplications suchasbreastcancer,uterine
bleeding, and cardiovascular events. One concern related to the
usage of bisphosphates is the complications of osteonecrosis
of the jaw (ONJ). The incidence of ONJ disease seems relatively
low in patients receiving oral bisphosphates for osteoporosis
or Paget’s disease and considerably higher in patients with
malignancy receiving high doses of intravenous bispho-
sphates.
(7,8) Despite an excellent safety profile for parathyroid
hormone (PTH), concerns do arise from its persistence after
discontinuation without sequential use of antiresorptive
drugs.
(9,10) In addition, PTH is not recommended for patients
withariskofosteosarcoma.Thebeliefthatcombineduseofboth
types of drugs may have a synergistic effect on BMD is not fully
supported by some observational studies.
(11,12) These potential
limitations of existing drugs are sufficient to warrant a develop-
ment of novel therapies.
Because of the strong association of osteoporosis with
heritability, a large number of studies have been performed
with either candidate-gene or genome-wide screening strate-
gies. A highly resourced study using a combined linkage and
association analysis has linked the Bmp2 gene to a combined
phenotype of low BMD and high fracture risk.
(13) Polymorphisms
in the Bmp4 gene are associated with senile osteoporosis.
(14) In
fact, several small-molecular-weight compounds have been
identified by their stimulatory effect on Bmp2 gene expression. It
has been reported that statins stimulate bone formation by
upregulation of bone morphogenetic protein 2 (BMP-2)
activity.
(15) A similar effect is observed with proteosome
inhibitors and microtubule inhibitors that induce Bmp2 expres-
sion through inhibition of Glioma-associated oncogene2 (Gli2)
and (Gli3) degradation.
(16–18) BMP-2 acts on bone cells by
binding to their cell surface receptors and subsequently
phosphorylatingSmads1/5/8.PhosphorylatedSmads1/5/8forms
a complex with Smad4 and translocates to the nucleus, whereby
it regulates the transcription of bone-specific genes.
(19–23)
Emerging evidence suggests that BMP-2 has an ameliorative
effect on osteoporosis.
(24) Therefore, it is desirable to identify
compounds capable of inducing endogenous BMP-2 production
in bone cells.
To explore the alternative anabolic drugs for the treatment of
osteoporosis, this study aimed to investigate the in vivo effects
of Osthole, a derivative of Chinese herb medicine, on bone
formation using the calvarial local injection mouse model and
the ovariectomy rat model. We found that Osthole stimulates
new bone formation after its local injection over the surface
of calvaria. Osthole is also capable of significantly reversing
ovariectomy-induced bone loss in rats. Concerning fragile
fracture, we examined the effect of Osthole on the biomecha-
nical properties of the femoral diaphysis in ovariectomized rats
and found that it significantly enhanced bone mechanical
strength. In vitro studies demonstrated that Osthole-induced
osteoblast differentiation through activation of Wnt/b-catenin–
BMP signaling in osteoblasts.
Materials and Methods
In vivo periosteal bone-formation assay
All surgical protocols related to the use of mice were approved
by the University of Rochester Institutional Review Board. Four-
week-old ICR Swiss mice were injected subcutaneously over the
calvarial surface with or without the treatment of Osthole twice a
day for 5 consecutive days at the doses of 1 and 5mg/kg per day
(3micepergroup).MicrotubuleinhibitorTN-16(CalBiochem,San
Diego, CA, USA) was used as a positive control (5mg/kg per day,
by subcutaneous injection, twice a day for 2 days; 3 mice per
group).
(17)Allmicewereeuthanized3weeksaftertreatment,and
calvariae were dissected, fixed in 10% phosphate-buffered
formalin for 2 days, decalcified in 10% EDTA for 2 weeks,
and embedded in paraffin. Histologic sections were cut and
stained with hematoxylin and eosine (H&E) orange G. New bone
area over the calvarial surface was quantified by histomorpho-
metry using the OsteoMeasure System (OsteoMetrics, Inc.,
Atlanta, GA, USA). To measure mineral appositional rate (MAR)
and bone-formation rate (BFR), double calcein labeling was
performed at days 7 and 14 by intraperitoneal injection (20mg/
kg), and mice were euthanized 7 days after the second labeling.
The labeling was examined in plastic sections. The dissected
calvarial samples were fixed in 75% ethanol and embedded in
methyl methacrylate. Unstained transverse sections (3mmt h i c k )
were examined with a fluorescent microscope. MAR and BFR were
measuredusingtheOsteoMeasureSystem(OsteoMetrics,Inc.).
(25,26)
Rat ovariectomy surgery
All surgical protocols related to the rat ovariectomy experiment
wereapprovedbythe EthicalCommitteeofShanghaiLaboratory
Animal Center. Thirty 6-month-old female Sprague-Dawley rats
were purchased from the SLAC Laboratory Animal Co., Ltd.
(Shanghai, China). After anesthesia with intraperitoneal nembu-
tal injection (30mg/kg), the rats were randomized by body
weight into three groups for the surgery (n¼10/group): group 1:
sham surgery followed by PBS vehicle treatment (sham þ VEH);
group 2: ovariectomy followed by vehicle treatment (OVX þ
VEH); and group 3: ovariectomy followed by Osthole treatment
(OVX þ OST). The treatment was started 1 month after surgery
and continued for 8 weeks. Vehicle or Osthole (100mg/kg per
day) was administered orally once a day for 8 weeks. Before rats
were euthanized at the end of the experiments, the total bone
mineral density (BMD, g/m
2) was measured using dual-energy
X-ray absorptiometry (Hologic, Inc., Waltham, MA, USA). The
fourth lumbar vertebrae (L4) then were dissected for histomor-
phometric and micro-computed tomographic (mCT) analysis,
and the left femoral shafts were used for biomechanical
testing.
mCT analysis
The fourth lumbar vertebrae (L4) were scanned at 18-mm voxel
size using the mCT scanner (mCT80, Scanco Medical AG,
Bassersdorf, Switzerland). The trabecular bone under the growth
plate was segmented using a contouring tool, and the contours
were morphed automatically to segment the trabecular bone on
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evaluation software of the mCT system.
Histomorphometric analysis
The fourth lumbar vertebrae (L4) were fixed in 70% ethanol and
embedded in methyl methacrylate. Midsagittal sections (50mm)
werecut with aLEICA SM2500E Microtome (LEICA, Heidelberger,
Germany). Histomorphometric analysis of the trinitrophenol
poinsettia–stained sections was performed with an image
autoanalysis system (Olympus BX50, Olympus, Tokyo, Japan).
The trabecular bone was measured in the area of the secondary
spongiosa 0.5mm apart from the growth plate (2-mm area). All
values were represented as the mean of three measurements in
three nonconsecutive sections. Histomorphometric parameters
were calculated and expressed according to the recommenda-
tions made by the American Society for Bone and Mineral
Research (ASBMR) nomenclature committee.
(27) The image
analysis system automatically determined the measuring areas,
andthestructuralparameterswerepresentedastrabecularbone
volume (BV/TV, %), trabecular thickness (Tb.Th, mm), trabecular
number (Tb.N, 1/mm), and trabecular separation (Tb.Sp, mm).
Biomechanical testing
After careful removal of soft tissue, the femoral samples were
incubated in PBS for 3 hours for thorough hydration. To
determine the changes in mechanical properties, the femoral
shafts were tested to failure via three-point bending using an
Instron Dynamite 8841 servohydraulic material-testing device
equipped with a 1-kN load cell, and the data collection was
performed with Bluehill software (Instron, Norwood, MA, USA).
The anterior surface of the femoral shaft was placed on the two
support beams separated by an 8-mm span. The femurs were
bent to failure along the mediolateral axis at a rate of 0.10mm/s.
Force and deformation data were analyzed and represented as
the bending stiffness (N/mm).
(28)
Primary cell isolation and culture
Calvariae from neonatal mice were removed, subjected to a
series of collagenase A (Roche, Indianapolis, IN, USA) digestions
at 378C with shaking, pooled, and then plated on 25cm
2 flasks in
a modified essential medium (a-MEM, Invitrogen, Carlsbad, CA,
USA). Cells were maintained in a-MEM plus 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (Invitrogen) and
were cultured with 5mM of b-glycerophosphate, 100mM of L-
ascorbic acid, and 0.1mM of dexamethasone (Sigma, St. Louis,
MO, USA) in basic medium for osteoblast differentiation. Cell
culture medium was changed every 3 days.
Cell viability assay
Primary calvarial osteoblasts were seeded in 96-well plates at a
density of 0.5 10
4 cells per well. After 2 days of culture, cells
were treated withOsthole atconcentrations of0, 1, 5, 10,50, 100,
500, and 1000mM for 48 hours (6 wells per group). Cell culture
medium then was removed, and 100mL of CellTiter Blue and
medium (Promega, Madison, WI, USA) were added to each well
of the plate. After incubated for 4 hours, the fluorescence was
read at excitation/emission wavelengths of 560/590nm in a
FLUO-STAR plate reader (Promega).
Real-time quantitative polymerase chain reaction (qPCR)
Primary calvarial osteoblasts were seeded in 6-well plates at a
density of 5 10
6 cells per well. After 2 days of culture, cells were
treated with Osthole at concentrations of 10, 50, and 100mMo r
BMP-2 (100ng/mL) (R&D Systems, Minneapolis, MN, USA) for
48 hours (6 wells per group). Total RNA from each well was
isolated separately using RNeasy Mini Kit (Qiagen, Valencia, CA,
USA). Then 1mg of RNA from each well was reverse transcribed
separately into cDNA using the iScript cDNA Synthesis Kit (Bio-
Rad, Hercules, CA, USA). The cDNA then was amplified by PCR
(958C for 15 minutes followed by 45 cycles, 958C for 20 seconds,
588C for 20 seconds, and 728C for 30 seconds) with Absolute
QPCR SYBR Green Master Mix (Thermo Scientific, Waltham, MA,
USA) in a total volume of 20mL of buffered solution containing
1mL of the diluted (1:5) reverse-transcription product in the
presence of 10pM ofsense andantisense primers specific for the
genes listed in Table 1.
Table 1. Mouse Primers for Real-Time qPCR Assays
Genes Forward primer Reverse primer
b-actin TGTTACCAACTGGGACGACGACA CTGGGTCATCTTTTCACGGT
ALP TGACCTTCTCTCCTCCATCC CTTCCTGGGAGTCTCATCCT
Bmp2 ACTTTTCTCGTTTGTGGAGC GAACCCAGGTGTCTCCAAGA
Bmp4 GAGGAGGAGGAAGAGCAGAG TGGGATGTTCTCCAGATGTT
Bmp6 CTCAGAAGAAGGTTGGCTGG ACCTCGCTCACCTTGAAGAA
Wnt1 ACAGCGTTCATCTTCGCAATCACC AAATCGATGTTGTCACTGCAGCCC
Wnt3a GGCTCCTCTCGGATACCTCT GGGCATGATCTCCACGTAGT
Wnt4 CTCAAAGGCCTGATCCAGAG GTCCCTTGTGTCACCACCTT
Col1a1 CCTGGTAAAGATGGGCC CACCAGGTTCACCTTTCGCACC
Runx2 TCCTGTAGATCCGAGCACCA CTGCTGCTGTTGTTGCTGTT
BSP AGGACTGCCGAAAGGAAGGTTA AGTAGCGTGGCCGGTACTTAAA
OC CTTGAAGACCGCCTACAAAC GCTGCTGTGACATCCATAC
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AftertreatmentwitheitherBMP-2orOstholefor48hours(4wells
per group), primary calvarial osteoblasts were lysed with passive
lysis buffer (Promega). Protein concentrations were determined
by Coomassie Protein Assay Kit (Bio-Rad) and alkaline phospha-
tase (ALP) activities were analyzed with solutions containing
0.5mg/mL of p-nitrophenyl-phosphate (Sigma) in AMP buffer
(0.5M 2-methyl-1,2-aminopropanol and 2mM magnesium
chloride, pH 10.3) at 37 8C for 15 minutes. The reaction was
stopped by a solution containing 0.3M sodium phosphate (pH
12.3), and ALP activity data were normalized by the protein
concentration. For the ALP staining assay, after treatment with
either BMP-2 or Osthole for 48 hours, primary calvarial osteo-
blastswerefixedin10%neutralbufferedformalinfor15minutes,
washed, and then incubated with ALP staining buffer NBT-BCIP
(Bio-Rad) at 37 8C for 30 minutes (n¼3).
For the nodule-formation assay, primary calvarial osteoblasts
were seeded in 6-well plates at a density of 5 10
6 cells per well
a n dc u l t u r e df o r2d a y si na-MEM supplemented with 100mg/mL
ascorbic acid and 5mM b-glycerophosphate. Cells then were
treated with Osthole at concentrations of 10, 50, and 100 mM
orBMP-2(100ng/mL)(3wellspergroup).Cellculturemediumwas
changed every 3 days, and fresh medium and reagents were
added. After 14 days of incubation, cells were stained with 2%
alizarin red to analyze formation of mineralized bone nodules.
Western blot analysis
To examine the effect of Osthole on BMP-2 expression and on
BMP signaling, primary calvarial osteoblasts were seeded in
6-well plates at a density of 5 10
6 cells per well. After 2 days of
culture, cells were treated with Osthole at concentrations of 10,
50, and 100 mM for 48 hours. Cell lysates were extracted with
E-PER protein extraction reagents (Thermo Scientific, Waltham,
MA, USA) according to the manufacturer’s protocol. Proteins
were transblotted onto a PVDF membrane (Bio-Rad), and the
membrane was blocked with 5% milk in phosphate buffered
saline containing, 0.1% Tween-20 (PBST) for 1 hour at room
temperature. After incubation with the primary antibody
overnight at 4 8C and the horseradish peroxidase (HRP)–
conjugatedsecondaryantibodies(ThermoScientific)for1hours
at room temperature, protein expression was detected using a
SuperSignal West Femto Maximum Sensitivity Substrate Kit
(Thermo Scientific). The polyclonal rabbit BMP-2 antibody was
obtained from Abcam (Cambridge, MA, USA), and the
polyclonal rabbit anti-b-catenin antibody was obtained from
Cell Signaling Technologies (Beverly, MA, USA). After the
immunocomplex was removed by stripping buffer (Chemicon,
Inc., Temecula, CA, USA), the same membrane was reblotted
with mouse anti-b-actin antibody (Sigma) for the loading
control. To examine the effect of Osthole on Smad1/5/8
phosphorylation, mouse primary osteoblasts were treated with
eitherOsthole(100mM)orBMP-2(100ng/mL) intheabsenceor
presence of noggin (300ng/mL, R&D Systems) for 2 hours. After
cell lysis, Western blotting was performed using rabbit
anti-phospho-Smad1/5/8 polyclonal antibody (Cell Signaling
Technologies).
Immunofluorescence labeling and confocal microscopy
Primary mouse osteoblasts were seeded at a density of 1 
10
3 cells per well in 4-well chamber slides (Nalgene, Rochester,
NY, USA) for 24 hours and then treated with Osthole (100 mM)
or BMP-2 (100ng/mL) for 2 hours (n¼3). After washes with PBS,
cells were fixed with acetone/methanol (1:1) at 4 8C for
30 minutes. Nonspecific binding was blocked by incubation
with PBS containing 10% normal goat serum at room
temperature for 1 hour. After excess serum was removed, rabbit
antibody against phospho-Smad1/5/8 (1:50 dilution) in PBS
containing 10% goat serum and 0.1% saponin (Research
Organics, Inc., Cleveland, OH, USA) was applied to slides and
incubated overnightat48C.AfterthoroughwasheswithPBS, the
slides were incubated in the dark for 1 hour with fluorescein
isothiocyanate (FITC)–conjugated goat anti-rabbit secondary
antibody (1:100 dilution; Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) in PBS containing 0.1% saponin and 10%
goat serum. The slides then were rinsed with tap water for
30 minutes and mounted with VECTASHIELD medium (Vector
Laboratories, Burlingame, CA, USA). Immunofluorescence was
detected with a Zeiss microscope using appropriate filters.
Plasmid transfection and luciferase assay
Primary mouse osteoblasts were seeded at a density of 1 
10
4 cells per well in 96-well plates and cultured. The BMP
signaling reporter construct 12 SBE-OC-Luc
(29) was transfected
into primary osteoblasts using FuGENE HD Transfection Reagent
(Invitrogen). An SV40-Renilla luciferase construct was cotrans-
fected with the preceding firefly reporter construct as an internal
control to normalize transfection efficiency. Cells were incubated
with Osthole at concentrations of 0, 10, 50, and 100 mM or BMP-2
(100ng/mL) for 48 hours (6 wells per group). Cell lysates then
were extracted, and luciferase activity was measured using a
Promega luciferase assay kit (Promega).
In vitro deletion of the b-catenin and Bmp2 genes
Theb-catenin
fx/fxmiceweregenotypedandidentifiedbyPCRusing
the following primers: upper primer 5’- AAGGTAGAGTGAT-
GAAAGTTGTT-3’ and lower primer 5’- CACCATGTCCTC
TGTCTATTC-3’ (324-base-pair PCR product). The Bmp2
fx/fx mice
weregenotypedandidentifiedbyPCRusingthefollowingprimers:
wild-type allele: upper primer 5’-AGGGTTTCAGGTCA- GTTTCCG-3’
and lower primer 5’-TCCGAAGGTAAGTGTGCTTGG-3’ (200-base-
pair PCR product); and Bmp2-floxed allele: upper primer 5’-
AGGGTTTCAGGTCAGTTTCCG-3’ and lower primer 5’-GATGAT-
GAGGTTCTTGGCGG-3’ (400-base-pair PCR product). Primary
calvarial osteoblasts isolated from the b-catenin
fx/fx and Bmp2
fx/fx
mice were seeded in 6-well culture plates at a density of 5 10
6
cellsperwellandculturedfor2days(n¼3).Adenovirusexpressing
Cre recombinase (Ad-Cre, 4 10
8 pfu/mL; Baylor College of
Medicine,Houston,TX,USA)wasaddedtotheculturedosteoblasts
for 3 days. Ad-GFP was used as a control and to monitor infection
efficiency. After recovery for 2 days, cells were treated with or
withoutOsthole(100mM)for48hours.qPCRandWesternblotting
wereperformedtoconfirmtheinfectionefficiencyofAd-Cre.qPCR
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collagen, Runx2, OC, ALP,a n dOPN.
Statistical analysis
Data were expressed as mean SEM. Statistical comparisons
with results of multiple groups were analyzed using one-way
ANOVA followed by Dunnett’s test. For experiments involving
two groups, unpaired Student’s t test was performed.
Results
Osthole increased new bone formation
Ostholeisacoumarinderivativeandisalsoknownas7-methoxy-
8-isopentenoxycoumarin (Fig. 1A). It was extracted and purified
from Cnidium monnieri and Angelica pubescens plants by
supercritical CO2 method with over 98% purity as determined
by HPLC. Subcutaneous injection of Osthole at a dose of 5mg/kg
per day onto mouse calvariae significantly stimulated local bone
formation, as shown by histologic analysis of calvarial samples
harvested 2 weeks after the last injection and stained with H&E
orange G. Histomorphometric analysis revealed that Osthole had
a significant effect on bone formation as potent as the positive
control, the microtubule inhibitor TN-16.
(17) This effect, however,
was not seen when Osthole was used at a dose of 1mg/kg per
day (Fig. 1B, C). To further confirm whether Osthole stimulates
new bone formation on calvariae, Osthole injection (5mg/kg per
day) onto mouse calvariae was followed by calcein double
labeling on days 7 and 14. Mice were euthanized 7 days after
the second labeling, and histomorphormetric analysis showed
a significant difference between control and Osthole-treated
groups, demonstrated by an increased mineral appositional rate
(MAR) and bone-formation rate (BFR) (Fig. 1D–F).
Osthole prevents bone loss in ovariectomized rats
We then further analyzed the systemic effect of Osthole on
ovariectomy-induced bone loss. mCT 3D image analysis of the
fourth lumbar vertebrae (L4) demonstrated an apparent bone
loss in the ovariectomized rats compared with those that
underwent sham surgery. Intraperitoneal injection of Osthole for
8 weeks significantly reversed bone loss in the ovariectomized
rats (Fig. 2A). Histologic examination of the L4 samples stained
with trinitrophenol poinsettia demonstrated a partial recovery of
the trabecular structure in ovariectomized rats treated with
Osthole (Fig. 2B). Histomorphometric analysis showed that
treatment with Osthole significantly increased total BMD,
trabecular bone volume, and trabecular thickness and decreased
trabecular separation (Fig. 2C–F). In addition, osteoclast numbers
and osteoclast surface were decreased significantly in rats
treated with Osthole (data not shown), suggesting that reduced
osteoclast formation also may contribute to the increased bone
mass phenotype in Osthole-treated animals.
Fig. 1. Osthole stimulates local bone formation in mouse calvaria. (A) The chemical structure of the coumarin-like structure of Osthole. (B, C) Osthole was
injected subcutaneously over the surfaces of the calvaria (1 and 5mg/kg/day 5 days) of 4-week-old ICR Swiss mice. TN-16 was used as a positive control
(5mg/kg/day 2 days). Mice were euthanized 3 weeks after Osthole injection. H&E orange G staining of calvarial sections showed that Osthole (5mg/kg/
day) significantly induced new bone formation (black arrows). (B) Histomorphometric analysis showed that Osthole (5mg/kg/day) significantly increased
the total new bone area (group 4). (C–F) Calcein double labeling was performed in the mice treated with either vehicle or Osthole (5mg/kg/day 5 days).
Representative pictures taken under ultraviolet (UV) light from undecalcified sections showed that Osthole induced calvarial new bone formation (D).
Mineral appositional rate (MAR) (E) and bone formation rate (BFR) ( F) were quatified. Significant increases in MAR and BFR in Osthole-treated group were
observed.
 
p<.05, unpaired Student’s t test (compared with vehicle control).
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To further determine if the treatment with Osthole improves
biomechanical properties of bone, a three-point bending test
was performed on femoral shaft samples obtained from three
different groups. Ovariectomy caused a dramatic reduction in
maximal force (the maximal force that causes bone fracture),
yield force (the applied force that creates permanent bone
damage), and bone stiffness (the flexible ability against bone
distortion). Treatment with Osthole for 8 weeks significantly
reversed the reduced maximal force, yield force, and stiffness
caused by ovariectomy (Table 2), indicating that Osthole
improves bone biomechanical properties of ovariectomized rats
significantly.
Osthole stimulates osteoblast differentiation
Assessment of cell viability did not detect obvious toxicity when
Osthole was used at a dose up to 100mM. However, when the
dose reached 500mM, Osthole started to show toxic effect
(Fig. 3A). Based on these observations, Osthole was used in all in
vitro studies at the dose range of 10 to 100mM. Osthole dose-
dependently promoted osteoblast differentiation, as shown by
the upregulation of osteoblast differentiation marker genes such
as type I collagen (col1), bone sialoprotein (BSP) and osteocalcin
(OC) (Fig. 3B–D) (2 days of culture). The long-term culture (days 6
Fig. 2. Osthole reverses bone loss induced by ovariectomy in rats. Fourth lumbar vertebrae (L4) samples were obtained from the rats of the following
groups:(1)shamsurgerywithvehiclecontrol(shamþVEH),(2)ovariectomywithvehiclecontrol(OVXþVEH),and(3)ovariectomywithOstholetreatment
(OVX þ OST, 100mg/kg/day). The Osthole treatment was started 1 month after surgery and lasted for 8 weeks (oral administration, daily treatment). mCT
3D images of L4 samples (A) and histologic sections of L4 samples stained with trinitrophenol poinsettia (B) were obtained and analyzed. Bone
histomorphometric analysis showed that total BMD (C), trabecular bone volume (BV/TV, %) (D), trabecular thickness (Tb.Th, mm) (E) were significantly
increase and trabecular separation (Tb.Sp, mm) ( F) was significantly reduced in Osthole-treated rats compared with the vehicle-treated control
group.
 
p<.05, unpaired Student’s t test (OVX þ VEH group versus sham þ VEH group) and
  p<.05, unpaired Student’s t test (OVX þ OST group
versus OVX þ VEH group).
Table 2. Osthole Improves the Biomechanical Properties of
Mouse Shafts (Three-Point Bending Test)
Group
Maximum
force (N)
Yield
force (N)
Stiffness
(N/mm)
1. ShamþVEH 124.9 12.5 106.1 24.3 155.1 64.7
2. OVXþVEH 99.7 15.1
  77.3 37.4
  87.2 24.4
 
3. OVXþOST 120.9 13.7
   102.8 23.9
   119.0 33.6
  
Mean SE.
 p<.05, unpaired Student’s t test (OVX þ VEH versus sham
þ VEH);
  p<.05, unpaired Student’s t test (OVX þ OST versus OVX
þ VEH).
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from1 to100mM.(B–D)Osthole(10,50,and100mM)wasaddedtothecultureofprimarymousecalvarialosteoblastsfor2 days.Real-timeqPCRassaywas
performed to examine changes in expression of osteoblast marker genes including type I collagen (B), bone sialoprotein (C), and osteocalcin (D)( n¼6).
Ostholesignificantlyincreasedtheexpressionofosteoblastmarkergenesinadose-dependentmanner.BMP-2wasusedasapositivecontrol.(E)Thelong-
termcultureofprimarymouseosteoblastsfurtherdemonstratedthatOstholesignificantlyincreasedosteocalcinexpressioninday6andday12culturesin
a dose-dependent manner up to 13-fold (n¼6). ( F, G) ALP activity ( F) and ALP staining (G) assays were performed. Osthole significantly increased ALP
activity in primary osteoblasts (n¼3). (H) Primary mouse osteoblasts were cultured with or without Osthole (10, 50, and 100mM) for 14 days. Mineralized
bonenoduleformationwasmeasuredbyalizarinredstaining.Ostholesignificantlyincreasedbonenoduleformation(n¼3).BMP-2wasusedasapositive
control.
 
p<.05, one-way ANOVA followed by Dunnett’s test (Osthole versus control) and unpaired Student’s t test (BMP-2 versus control).
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expression, with up to a 13-fold increase (Fig. 3E). Alkaline
phosphatase (ALP) activity is another important indicator for
osteoblast differentiation, and we measured ALP activity and
performed an ALP staining assay 2 days after treatment with
Osthole. We found that Osthole promoted ALP activity in mouse
primary osteoblasts in a dose-dependent manner (Fig. 3F, G).
To determine the effect of Osthole on osteoblast terminal
differentiation, we carried out long-term cultures (14 days) using
primary mouse osteoblasts and performed alizarin red staining.
We found that addition of Osthole to the cell culture significantly
enhanced bone nodule formation in primary osteoblasts
(Fig. 3H).
Osthole activates BMP signaling
BMPs have been shown to play an important role in osteoblast
differentiation.TodeterminethemechanismofOstholeeffecton
osteoblast differentiation, we examined the effect of Osthole on
Bmp expression and BMP signaling. We found that Osthole
enhanced Bmp2 mRNA and protein expression in a dose-
dependent manner (Fig. 4A, B). In contrast, Osthole had no
significant effect on the expression of Bmp4 and Bmp6, at least at
the mRNA expression level (data not shown). To determine if
Osthole activates downstream signaling molecules of BMP, we
examined the effect of Osthole on Smad protein phosphoryla-
tion. Primary mouse osteoblasts were treated with 100mMo f
Osthole. The results demonstrated that Osthole significantly
enhanced phosphorylation of Smad1/5/8 in osteoblasts (Fig. 4C).
BMP-2 was used as a positive control and also showed
stimulation of Smad1/5/8 phosphorylation. Addition of noggin,
a BMP antagonist, completely inhibited BMP-2- and Osthole-
induced Smad1/5/8 phosphorylation (Fig. 4C), indicating that
Osthole-inducedSmad1/5/8phosphorylationisduetoactivation
of BMP expression. Immunofluorescent labeling showed that
Osthole also induced a rapid nuclear translocation of phospho-
Smad1/5/8 2 hours after treatment (Fig. 4D). To further confirm
the role of Osthole on BMP signaling, we also examined the
effectofOsthole onthe BMPsignaling reporter 12 SBE-OC-Luc.
Consistent with the preceding findings, Osthole significantly
stimulated the luciferase activity of the BMP signaling reporter in
a dose-dependent manner (Fig. 4E). Taken together, these
findings demonstrate that Osthole may regulate osteoblast
differentiation through activation of BMP signaling.
Osthole activates canonical Wnt/b-catenin signaling
Our recent studies demonstrate that Bmp expression is activated
by canonical Wnt/b-catenin signaling in chondrocytes and in
bone marrow stromal cells.
(28,30,31) To determine if Osthole
Fig. 4. Osthole activates BMP-2 signaling. (A, B) Primary mouse osteoblasts were cultured with or without Osthole (10, 50, and 100 mM) for 2 days.
Expression levels of Bmp2mRNA (A) and protein (B) were measured by real-time PCR and Western blotting. Osthole significantly increased Bmp2mRNA
and protein expression. (C) The effect of Osthole on Smad1/5/8 phosphorylation was examined using an anti-phospho-Smad1/5/8 antibody.
Osthole (50mM) significantly increased Smad1/5/8 phosphorylation. Addition of noggin completely inhibited Osthole-induced Smad1/5/8 phosphoryla-
tion. As a positive control, BMP-2 induced Smad1/5/8 phosphorylation. However, Osthole cannot further enhance BMP-2-induced Smad1/5/8
phosphorylation. (D) Osthole significantly increased phospho-Smad1/5/8 nuclear translocation in primary osteoblasts, demonstrated by immunofluore-
scence labeling using the anti-phospho-Smad1/5/8 antibody. (E) In addition, Osthole (50 and 100mM) significantly increased luciferase activity of BMP
signaling reporter 12 SBE-OC-Luc (n¼6).
 
p<.05, one-way ANOVA followed by Dunnett’s test (Osthole versus control) and unpaired Student’s t test
(BMP-2 versus control).
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Osthole on mRNA expression of Wnt ligands, b-catenin protein
expression, and b-catenin signaling reporter. We found that
Osthole induced Wnt1, Wnt3a, and Wnt4 expression in a dose-
dependent manner (Fig. 5A–C). As a consequence, Osthole also
reduced phosphorylated b-catenin protein levels and enhanced
total b-catenin protein levels in primary calvarial osteoblasts
(Fig. 5D, E). High dosesof Osthole (50 and 100mM) also increased
TOPGAL (b-catenin signaling reporter) activity (Fig. 5F). As a
consequence of activation of b-catenin signaling, the expression
of b-catenin downstream target genes, such as axin2 and dkk1,
alsowasincreased(datanotshown).Thesefindingsdemonstrate
that Osthole also activates canonical Wnt/b-catenin signaling in
osteoblasts.
Osthole-induced osteoblast differentiation is b-catenin-
and BMP-2-dependent
To further determine if the effect of Osthole on osteoblast
differentiation depends on its stimulatory effect on b-catenin
and BMP-2 signaling, we used the in vitro gene-deletion
approach. Primary osteoblasts were isolated from the calvaria of
the b-catenin
fx/fx or Bmp2
fx/fx mice and infected with either Ad-
GFP or Ad-Cre. The cells then were treated with Osthole for
additional 2 days, and the effects of Osthole on the expression of
osteoblast marker genes were examined. Ad-GFP infection
revealed that high infection efficiency (>80%) was achieved in
primary osteoblasts (Fig. 6A). Ad-Cre infection in primary
osteoblasts isolated from the b-catenin
fx/fx mice inhibited
Osthole-induced expression of Runx2, ALP, and BSP, as well as
Bmp2 (Fig. 6B–E). In contrast, Ad-Cre infection in primary
osteoblasts isolated from the Bmp2
fx/fx mice significantly
inhibited Osthole-induced expression of Runx2, ALP, and OC
(Fig. 7A–C) but had no effect on b-catenin expression (Fig. 7D).
Ad-Cre-mediated deletion of the Bmp2 gene was demonstrated
by the reduction of Bmp2 mRNA and protein expression in these
cells (Fig. 7E, F). These results suggest that Osthole induces
osteoblast differentiation through activation of b-catenin and
BMP-2 signaling. Since deletion of the b-catenin gene inhibited
Osthole-induced Bmp2 expression but Osthole-regulated b-
catenin expression was not affected by deletion of the Bmp2
gene, these findings also suggest that Bmp2 may act down-
stream of b-catenin signaling, and Osthole activates osteoblast
differentiation through b-catenin–BMP-2 signaling pathway.
Fig. 5. OstholestimulatescanonicalWntsignaling.(A–D)PrimarymouseosteoblastswereculturedwithorwithoutOsthole(10,50and100mM)for2days.
ExpressionlevelsofWnt1,Wnt3a,andWnt4mRNA(A–C)andproteinlevelsofphosphorylationandtotalb-catenin(D)weremeasuredbyreal-timePCRand
Westernblotting.OstholesignificantlyincreasedmRNAexpressionofWnt1,Wnt3a,andWnt4(A–C).Ostholealsosignificantlyinhibitedphospho-b-catenin
and increased total b-catenin protein levels (D). (E) To examine the effect of Osthole on b-catenin signaling, the effect of Osthole on the activity of b-
catenin signalingreporter TOPGAL also wasexamined.Osthole significantly increasedluciferaseactivity of TOPGALreporter.
 
p<.05, unpaired Student’st
test (compared with vehicle control).
1242 Journal of Bone and Mineral Research TANG ET AL.Discussion
Osthole (7-methoxy-8-isopentenoxycoumarin) is a coumarin
derivative that is present in many plants such as Cnidium
monnieriandAngelicapubescens.IntraditionalChinesemedicine,
these plants have been used as tonics and aphrodisiacs and for
thetreatmentofbone-relateddiseases.
(32,33)Inaratosteoporosis
model induced by ovariectomy, Osthole prevents bone loss
through an estrogen-like effect.
(34) In addition to Osthole, other
coumarin derivatives from C. monnieri also have demonstrated
an ability to induce bone formation.
(35) Osthole has been
demonstrated to be able to stimulate proliferation in osteoblast-
like UMR106 cells.
(36) In vitro study also shows that Osthole has
no effect on cell proliferation to human osteoblast-like MG-63
cells or human fetal osteoblasts. Instead, Osthole stimulates
osteoblast differentiation.
(37) Although the effect of Osthole on
osteoblast differentiation has been suggested to be mediated by
BMPs, the detailed molecular mechanism has not been clearly
defined.
This study has demonstrated the in vivo effect of Osthole by
local and systemic administrations of Osthole into mice and rats.
We found that Osthole induces new bone formation on the
surfaces of mouse calvaria. Histomorphometric analysis shows
that Osthole accelerates osteoid formation and mineralization.
To more closely mimic the clinical scenario of the treatment
of postmenopausal osteoporosis, we started systemic Osthole
administration 4 weeks after ovariectomy and continued
treatment for 8 weeks. The effects of Osthole on the structural
and biomechanical properties of the bone in ovariectomized rats
were monitored with mCT, histomorphometric, and three-point
bending analyses. While ovariectomy significantly reduced bone
mass and strength, systemic Osthole administration largely
prevented its deleterious effects. The observation that Osthole
improved the biomechanical properties of bone in ovariecto-
mized rats is of particular importance with regard to the
treatment of fragile fracture in osteoporotic patients. The safety
profile further supports the clinical application of Osthole as a
novel anabolic agent for the treatment of osteoporosis.
To determine the mechanism by which Osthole promotes
osteoblast differentiation, we examined the effect of Osthole on
primary mouse calvarial osteoblasts by monitoring maturation
marker genes, ALP activity, and bone nodule formation.
Collectively, our in vitro studies indicate that Osthole stimulates
osteoblast differentiation and maturation. In these studies, we
havedemonstratedthatOstholeactivatesbothcanonicalWnt/b-
catenin and BMP-2 signaling in osteoblasts. We found that
deletion of either the b-catenin or Bmp2 gene in osteoblasts
significantly inhibited Osthole-induced osteoblast differentia-
Fig. 6. Osthole induces osteoblast differentiation in a b-catenin-dependent manner. Primary mouse osteoblasts were isolated from b-catenin
fx/fx mice,
infected with either Ad-GFP or Ad-Cre, and then treated with or without Osthole. Ad-GFP infection showed that primary osteoblasts were infected with
adenovirus with high efficiency (>80%) (A). The infection of Ad-Cre completely inhibited Osthole-induced Runx2, ALP, BSP, and Bmp2 expression (B–E).
 
p<.05, unpaired Student’s t test (compared with Ad-GFP group).
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Osthole-inducedBmp2expression,whereasdeletionoftheBmp2
gene did not affect Osthole-regulated b-catenin expression in
osteoblasts, these findings suggest that Bmp2 may serve as a
downstream target gene of b-catenin signaling in osteoblasts.
Osthole may stimulate osteoblast differentiation through
activation of Wnt/b-catenin–BMP-2 signaling pathway.
Targeted deletion of the Bmp2 gene only partially reverses the
effects of Osthole on osteoblast maturation. Several reasons for
this may exist. First, Osthole may induce Smad1/5/8 phosphor-
ylation by activating the MAP kinase pathway, as suggested by
Kuo and colleagues, and acts downstream of the Bmp2 gene.
Second, other BMPs may play a role in Osthole-induced
osteoblast differentiation. Indeed, our qPCR results show that
Osthole also upregulates the expression of Bmp7 mRNA,
although it has no obvious effect on the expression of Bmp4
and Bmp6.
In summary, this study clearly demonstrates that Osthole
induces new bone formation and prevents bone loss caused
by estrogen deficiency, and such effects are mediated by
inducing osteoblast differentiation. The end results of this
orchestrated activity are improved BMD and biomechanical
properties. Osthole may activate b-catenin–BMP-2 signaling
pathway to regulate osteoblast differentiation. Our future
research will focus on optimizing the pharmacokinetics
and pharmacodynamics of Osthole for possible oral admin-
istration.
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